Silexion Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
First patient dosed in the Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer
First patient dosed in the Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer